Nexalin Technology, Inc. (NXL) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Nexalin Technology, Inc. is a medical device company developing non-invasive neurostimulation products (Gen-1, Gen-2, and Gen-3) to treat anxiety, insomnia, and depression. The company is classified as a Smaller Reporting Company and an Emerging Growth Company. While Gen-1 devices are restricted in the U.S. pending new FDA applications, Gen-2 devices have received regulatory approval in China, Oman, and Brazil. The company operates a joint venture in China (48% ownership) for the development and distribution of Gen-2 devices.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Net Revenue | $36,031 | $24,113 | $141,542 | $90,212 |
| Gross Profit | $23,337 | $20,140 | $112,445 | $69,755 |
| Gross Margin | 64.8% | 83.5% | 79.4% | 77.3% |
| Net Loss | $(2,448,257) | $(2,297,189) | $(4,773,907) | $(3,868,040) |
| Loss Per Share (Basic/Diluted) | $(0.23) | $(0.31) | $(0.55) | $(0.53) |
| Cash & Equivalents | $81,421 (Sep 30, 2024) | |||
| Short-Term Investments | ||||
| Total Liquidity | $4,593,618 | |||
| Accumulated Deficit | $(81,811,956) | |||
| Working Capital | $4,608,200 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 49% quarter-over-quarter and 57% year-over-year (YTD), driven primarily by sales of supplies, parts, and new device sales to overseas customers (China).
- Operating Expenses: Total operating expenses increased 4% QoQ and 21% YTD. The increase is largely attributed to a $1.47M rise in stock-based compensation and higher professional fees (including executive search costs), partially offset by a decrease in R&D costs as clinical trial expenses were not incurred in 2024.
- Capital Raise: In July 2024, the company consummated a follow-on public offering of 3,000,000 shares, raising approximately $4.72 million in net proceeds. This capital infusion was critical to regaining compliance with Nasdaq's Minimum Stockholder Equity Rule.
- Investment Activity: Short-term investments increased from $2.37M (Dec 2023) to $4.51M (Sep 2024), reflecting the deployment of capital raised in the July offering.
Outlook, Risks, and Contingencies
- Liquidity and Going Concern: Management has concluded that current cash and short-term investments are insufficient to satisfy anticipated cash requirements for the next twelve months. The company expects to continue incurring operating losses and negative cash flows from operations. Continued viability depends on raising additional capital and generating revenue from the joint venture.
- Regulatory Status:
- U.S. (Gen-1): Marketing of Gen-1 devices for anxiety/insomnia is suspended pending a new 510(k) application. Depression treatment requires a Class III PMA.
- U.S. (Gen-2/Gen-3): Pre-submission documents for the 15-milliamp waveform have been filed. Clinical trials for Gen-3 are planned for Q4 2024.
- International: Gen-2 is approved in China (NMPA), Oman, and Brazil.
- Nasdaq Compliance: The company regained compliance with the Minimum Bid Price Rule in October 2024 after a period of non-compliance. It also regained compliance with the Minimum Stockholder Equity Rule following the July 2024 offering.
- Legal Proceedings:
- Sarah Veltz v. Nexalin: A lawsuit alleging unpaid wages and sexual harassment is pending, with a trial set for June 2025. Management intends to contest vigorously; no loss estimate can be provided.
- EDD Settlement: Discussions are ongoing with the California Employment Development Department regarding worker classification. An accrued liability of $40,000 is recorded.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and IT controls. Disclosure controls were deemed ineffective as of September 30, 2024.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the explicit "going concern" warning and insufficient funds for the next 12 months.
- Revenue Concentration: Note that five customers accounted for 75% of Q3 revenue and two customers accounted for 59% of YTD revenue, creating significant concentration risk.
- Stock-Based Compensation: Review the impact of non-cash stock compensation ($2.0M YTD) on operating expenses and potential future dilution.
- Regulatory Milestones: Monitor the status of the FDA 510(k) application for Gen-1 and the clinical trial results for Gen-3, which are critical for U.S. commercialization.
- Internal Control Remediation: Assess the progress and cost of remediation plans for the identified material weaknesses in financial reporting controls.